A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening.
Daniel C ChungDarrell M GrayHarminder SinghRachel B IssakaVictoria M RaymondCraig EagleSylvia HuDarya I ChudovaAmirAli TalasazJoel K GreensonFrank A SinicropeSamir GuptaWilliam M GradyPublished in: The New England journal of medicine (2024)
In an average-risk screening population, this cfDNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions. (Funded by Guardant Health; ECLIPSE ClinicalTrials.gov number, NCT04136002.).